Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 28Lymphoma, Follicular 17Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Mantle-Cell 6Lymphoma 5Lymphoma, B-Cell, Marginal Zone 4Lymphoma, B-Cell 3Leukemia 3Neoplasms 2Bronchiolitis Obliterans Syndrome 2Tumor Lysis Syndrome 1Solid Tumors 1Recurrence 1Oncology Patients Receiving Chemotherapy 1Neoplasm, Residual 1Neoplasm Metastasis 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphoid 1Leukemia, Hairy Cell 1Indolent Non-Hodgkin's Lymphoma 1Chromosome 17 deletion 1Carcinoma, Non-Small-Cell Lung 1B-cell Malignancies 1Anemia 1

Interventions

rasburicase 3Allopurinol 3Febuxostat 2venetoclax 1obinutuzumab 1alvocidib 1Urate Oxidase 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Tumor Lysis Syndrome × obinutuzumab × Clear all
NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

AbbVie

Phase 3 Completed
120 enrolled 14 charts
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡